BioCentury | Dec 7, 2009
Company News

StemCyte, Academia Sinica deal

...of stem cell to treat chronic stroke. The university's technology is in Phase II testing. StemCyte...
...to develop and commercialize adult stem cells for the indication. Further terms were not disclosed. StemCyte Inc....
BioCentury | Mar 3, 2008
Company News

StemCyte, Rutgers University deal

...The university will study StemCyte’s human umbilical cord blood stem cells in conjunction with lithium as...
...blood stem cells in conjunction with lithium as a potential treatment for spinal cord injury. StemCyte...
...will receive undisclosed research funding and is eligible for royalties. Further details were not disclosed. StemCyte Inc....
BioCentury | May 17, 2004
Finance

Ebb & Flow

...five diversified funds. Its biotech portfolio includes biochip play Aviva and stem cell banking company Stemcyte...
Items per page:
1 - 3 of 3
BioCentury | Dec 7, 2009
Company News

StemCyte, Academia Sinica deal

...of stem cell to treat chronic stroke. The university's technology is in Phase II testing. StemCyte...
...to develop and commercialize adult stem cells for the indication. Further terms were not disclosed. StemCyte Inc....
BioCentury | Mar 3, 2008
Company News

StemCyte, Rutgers University deal

...The university will study StemCyte’s human umbilical cord blood stem cells in conjunction with lithium as...
...blood stem cells in conjunction with lithium as a potential treatment for spinal cord injury. StemCyte...
...will receive undisclosed research funding and is eligible for royalties. Further details were not disclosed. StemCyte Inc....
BioCentury | May 17, 2004
Finance

Ebb & Flow

...five diversified funds. Its biotech portfolio includes biochip play Aviva and stem cell banking company Stemcyte...
Items per page:
1 - 3 of 3